<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Pathol. Oncol. Res.</journal-id>
<journal-title>Pathology &#x26; Oncology Research</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Pathol. Oncol. Res.</abbrev-journal-title>
<issn pub-type="epub">1532-2807</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">629829</article-id>
<article-id pub-id-type="doi">10.3389/pore.2021.629829</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Society Journal Archive</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hyperoside Protects HK-2 Cells Against High Glucose-Induced Apoptosis and Inflammation <italic>via</italic> the miR-499a-5p/NRIP1 Pathway</article-title>
<alt-title alt-title-type="left-running-head">Zhou et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">The Role of Hyperoside</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Jingbo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Shu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Xinyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lou</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yu</surname>
<given-names>Jiangyi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Endocrinology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Department of Endocrinology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> Anna Sebesty&#xe9;n, Semmelweis University, Hungary</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Jiangyi Yu, <email>yujiangyimed@sina.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>27</volume>
<elocation-id>629829</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>11</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>02</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Zhou, Zhang, Sun, Lou and Yu.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Zhou, Zhang, Sun, Lou and Yu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Hyperoside, a flavonol glycoside, is derived from plants of the genera <italic>Hypericum</italic> and Crataegus. Recent studies have indicated the anti-apoptotic and anti-inflammatory roles of hyperoside. The present study was designed to measure the effects of hyperoside on high glucose (HG)-treated HK-2 cells. HK-2 is a human papillomavirus 16 transformed cell line and can be used as a model for normal tubular cell. Cell apoptosis was examined by TUNEL assays and flow cytometry analysis. Inflammatory response was detected by Enzyme linked immunosorbent assay kits. Western blotting was applied to detect protein levels of apoptosis-related genes and inflammatory cytokines. Mechanistical assays including luciferase reporter and RNA pull down assays were applied to detect the binding relationship between molecules. We identified that hyperoside protected HK-2 cells against HG-induced apoptosis and inflammation. Moreover, miR-499a-5p was upregulated by hyperoside in a dose dependent manner. MiR-499a-5p inhibition rescued the suppressive effects of hyperoside on apoptosis and inflammation of HG-treated HK-2 cells. Furthermore, miR-499a-5p targeted NRIP1 to inhibit its mRNA expression, and further suppressed its translation. NRIP1 was downregulated by hyperoside in a dose dependent manner. Finally, rescue assays indicated that miR-499a-5p inhibition rescued the protective effects of hyperoside on apoptosis and inflammatory response of HK-2 cells by NRIP1. In conclusion, our findings revealed that hyperoside alleviates HG-induced apoptosis and inflammatory response of HK-2 cells by the miR-499a-5p/NRIP1&#x20;axis.</p>
</abstract>
<kwd-group>
<kwd>hyperoside</kwd>
<kwd>HK-2 cells</kwd>
<kwd>apoptosis</kwd>
<kwd>inflammation</kwd>
<kwd>molecular biology</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Diabetic nephropathy (DN) is a common complication of type I or type II diabetes [<xref ref-type="bibr" rid="B1">1</xref>]. Approximately 30&#x2013;40% of diabetic patients are estimated to develop into DN [<xref ref-type="bibr" rid="B2">2</xref>]. Control on blood sugar, blood pressure, blood lipids, and diet intervention are mainly therapeutic strategies for DN [<xref ref-type="bibr" rid="B3">3</xref>]. Renal tubular damage induced by high glucose (HG) promotes the occurrence and development of DN [<xref ref-type="bibr" rid="B4">4</xref>]. Therefore, a comprehensive understanding of HG stimulated renal tubular damage contributes to seek the effective agents for&#x20;DN.</p>
<p>Accumulating studies have indicated the importance of apoptosis and inflammation during renal tubular cell injury [<xref ref-type="bibr" rid="B5">5</xref>]. Apoptosis can result in progressive loss of renal cell, and thereby induce tubular atrophy, glomerular sclerosis, and renal interstitial fibrosis [<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>]. B-cell lymphoma-2 (Bcl-2) ad B-cell lymphoma-2 Associated X (Bax) are key modulators of apoptosis belonging to the Bcl-2 family. Bcl-2 independently heterodimerizes with Bax to suppress cell death, and the BH4 domain within the N-terminal region of Bcl-2 is essential for its anti-apoptotic activity [<xref ref-type="bibr" rid="B9">9</xref>]. Abnormal inflammation can result in destroyed renal architecture, companied by increased levels of pro-inflammatory cytokines including interleukin (IL)-1&#x3b2;, IL-6 and decreased levels of anti-inflammatory cytokines including IL-10 [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. Therefore, therapeutic strategies that inhibit apoptosis and inflammatory response of renal tubular cells are urgently needed.</p>
<p>Plant-derived herbal products have been found to potentially reduce apoptosis and inflammation of renal tubular epithelial cells. Hyperoside (quercetin-3-O-galactoside) is a flavonol glycoside derived from plants of the genera <italic>Hypericum</italic> and Crataegus [<xref ref-type="bibr" rid="B12">12</xref>]. Previous investigations have indicated that hyperoside plays an anti-inflammatory role, for example, hyperoside reduces the anti-inflammatory activities in mouse peritoneal macrophages by inactivation of nuclear factor-&#x3ba;B [<xref ref-type="bibr" rid="B13">13</xref>]. Hyperoside alleviates HG-induced inflammation in human umbilical vein endothelial cells [<xref ref-type="bibr" rid="B14">14</xref>]. Hyperoside is a putative therapeutic drug for vascular inflammatory diseases by inactivation of the high mobility group box 1 pathway [<xref ref-type="bibr" rid="B15">15</xref>]. In addition, hyperoside exerts protective effect on rats with heart failure via suppression of myocardial apoptosis [<xref ref-type="bibr" rid="B16">16</xref>]. Hyperoside alleviates ischemia-reperfusion induced tubular cell apoptosis&#x20;[<xref ref-type="bibr" rid="B17">17</xref>].</p>
<p>HG-stimulated human renal proximal tubule (HK-2) cells were widely used as the <italic>in&#x20;vitro</italic> models of DN [<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>]. The present study was designed to investigate the effects of hyperoside on apoptosis and inflammation of HG-treated HK-2 cells. In addition, the putative downstream pathway of hyperoside was explored.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Bioinformatics Analysis</title>
<p>The targets of miR-499a-5p were predicted by starBase [<xref ref-type="bibr" rid="B21">21</xref>] under the parameters of medium stringency in Degradome data, strict stringency in CLIP data, 5 programs in program number.</p>
</sec>
<sec id="s2-2">
<title>Cell Culture and Treatment</title>
<p>Human renal proximal tubule (HK-2) cells and renal cell adenocarcinoma cells (786-O) were commercially provided by the American Type Culture Collection (ATCC, Rockville, IN, United&#x20;States). The HK-2 cells were cultured under a 5% CO<sub>2</sub> atmosphere at 37&#xb0;C in Dulbecco&#x2019;s modified Eagle medium (DMEM) containing% fetal bovine serum (FBS), streptomycin (100&#xa0;mg/ml) and penicillin (100&#xa0;units/mL, 1&#xa0;ml). Upon reaching 60% confluence rate, cells were conducted to serum-starvation for 12&#xa0;h. For HG treatment, HK-2 cells were cultured with 45&#xa0;mmol/L of glucose for 24&#xa0;h, while for control treatment, cells were cultured with 5.5&#xa0;mmol/L of glucose for 24&#xa0;h. Hyperoside at concentrations of 0, 10, 50, and 100&#xa0;&#x3bc;mol/L were applied to treat HK-2 cells at room temperature for 6&#xa0;h.</p>
</sec>
<sec id="s2-3">
<title>Cell Transfection</title>
<p>The short hairpin RNA targeting nuclear receptor-interacting protein 1 (NRIP1), termed sh-NRIP1, miR-499a-5p mimics and NC mimics were provided by Biomics Biotechnologies (Jiangsu, China). Before transfection, treated HK-2 cells (5 &#xd7; 10<sup>5</sup>&#xa0;cells/well) were inoculated into 6-well plates. Next, cells were transiently transfected with these oligonucleotides using Lipofectamine 3000 (Invitrogen, CA, United&#x20;States). Forty-eight hours after transfection, cells were harvested.</p>
</sec>
<sec id="s2-4">
<title>Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR)</title>
<p>Total RNA was extracted from treated HK-2 cells using the TRIzol reagent (Invitrogen). MiR-499a-5p was reverse transcribed into cDNA using a miRNA reverse transcription kit (Thermo Fisher Scientific). For NRIP1 reverse transcription, a PrimeScript reverse transcription reagent kit (Takara, Dalian, China) was applied. qPCR reactions were conducted on an ABI Prism 7500 RT PCR instrument (Applied Biosystems) using SYBR Premix Ex Taq (Takara). The thermocycling conditions were as follows: 50&#xb0;C for 2&#xa0;min, followed by 40 cycles of 95&#xb0;C for 15&#xa0;s and 60&#xb0;C for 1&#xa0;min. 2<sup>&#x2212;&#x394;&#x394;</sup>C<sub>t</sub> method [<xref ref-type="bibr" rid="B22">22</xref>] was utilized to analyze relative expression of miR-499a-5p or NRIP1 normalized to U6 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences for RT-qPCR are shown in <xref ref-type="table" rid="T1">Table&#x20;1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Primer sequences for RT-qPCR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="center">Relative primer sequences</th>
</tr>
<tr>
<th align="left">Molecules</th>
<th align="center">Sequences</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">miR-499a-5p</td>
<td align="left">Forward: 5&#x2032;-GCC&#x200b;CTG&#x200b;TCC&#x200b;CCT&#x200b;GTG&#x200b;CCT&#x200b;T-3&#x2032;</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Reverse: 5&#x2032;-AAA&#x200b;CAT&#x200b;CAC&#x200b;TGC&#x200b;AAG&#x200b;TCT&#x200b;T-3&#x2032;</td>
</tr>
<tr>
<td align="left">U6</td>
<td align="left">Forward: 5&#x2032;-TGC&#x200b;GGG&#x200b;TGC&#x200b;TCG&#x200b;CTT&#x200b;CGC&#x200b;AGC-3&#x2032;</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Reverse: 5&#x2032;-CCA&#x200b;GTG&#x200b;CAG&#x200b;GGT&#x200b;CCG&#x200b;AGG&#x200b;T-3&#x2032;</td>
</tr>
<tr>
<td align="left">NRIP1</td>
<td align="left">Forward: 5&#x2032;-GCT&#x200b;GGG&#x200b;CAT&#x200b;AAT&#x200b;GAA&#x200b;GAG&#x200b;GA-3&#x2032;</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Reverse: 5&#x2032;-CAAAGAGGCCAGT AATGTGCTATC-3&#x2032;</td>
</tr>
<tr>
<td align="left">GAPDH</td>
<td align="left">Forward: 5&#x2032;-AGG&#x200b;TCG&#x200b;GTG&#x200b;TGA&#x200b;ACG&#x200b;GAT&#x200b;TTG-3&#x2032;</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Reverse: 5&#x2032;-TGT&#x200b;AGA&#x200b;CCA&#x200b;TGT&#x200b;AGT&#x200b;TGA&#x200b;GGT&#x200b;CA-3&#x2032;</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-5">
<title>Cell Counting Kit-8 (CCK-8) Assay</title>
<p>A CCK-8 assay was used to measure cell viability. HK-2 cells (5 &#xd7; 10<sup>3</sup>&#xa0;cell/well) in different groups: control, HG, HG &#x2b; 1&#xa0;&#x3bc;mol/L of hyperoside, HG &#x2b; 10&#xa0;&#x3bc;mol/L of hyperoside, HG &#x2b; 50&#xa0;&#x3bc;mol/L of hyperoside, and HG &#x2b; 100&#xa0;&#x3bc;mol/L of hyperoside were inoculated into 96-well plate. After incubation, 10&#xa0;&#x3bc;L of CCK-8 solution (Dojindo, Kyushu, Japan) was added to culture plate and cells were incubated for another 1&#xa0;h&#xa0;at 37&#xb0;C. Optical density of each well was evaluated by a Microplate Reader at wavelength of 450&#xa0;nm.</p>
</sec>
<sec id="s2-6">
<title>Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay</title>
<p>Cell apoptosis was investigated by a TUNEL assay kit. Treated HK-2 cells (4 &#xd7; 10<sup>3</sup>&#xa0;cell/well) were seeded on chamber slides. After 48&#xa0;h of incubation, HK-2 cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and cultured with TUNEL reagents (Millipore; Merck KGaA, Darmstadt, Germany). TUNEL positive stained cells were observed by an optical microscope (Olympus, Tokyo, Japan).</p>
</sec>
<sec id="s2-7">
<title>Flow Cytometry Analysis</title>
<p>An apoptosis kit (Solarbio, Beijing, China) was used to measure apoptosis. HK-2 cells by different treatments were transferred to for. Cells were washed and resuspended in 100&#xa0;&#x3bc;L of 1&#x20;&#xd7; Binding Buffer after 5&#xa0;min of centrifugation in a centrifuge tube. Next, 5&#xa0;&#x3bc;L of Annexin V-FITC solution was added to the cells and cells were incubated at 37&#xb0;C for 15&#xa0;min in the dark. Afterward, cells were washed again and re-suspended in 200&#xa0;&#x3bc;L of 1&#x20;&#xd7; Binding Buffer, and 5&#xa0;&#x3bc;L of PI solution was added. Cell apoptosis rate was analyzed by flow cytometry within 1&#x2013;2&#xa0;h.</p>
</sec>
<sec id="s2-8">
<title>Western Blot</title>
<p>Western blotting was conducted according to a previous study [<xref ref-type="bibr" rid="B23">23</xref>]. The primary antibodies used in the study are listed as follows: anti-Bax (ab32503, 1/1000), anti-Bcl-2 (ab32124, 1/1000), anti-IL-10 (ab133575, 1/2000), anti-IL-6 (ab233706, 1/1000), anti-IL-1&#x3b2; (ab234437, 1/1000), and anti-GAPDH (ab9485, 1/2500).</p>
</sec>
<sec id="s2-9">
<title>Enzyme Linked Immunosorbent Assay (ELISA)</title>
<p>HK-2 cells by different treatments were centrifuged at 1,000 &#xd7; <italic>g</italic> for 20&#xa0;min. The levels of IL-10, IL-6 and IL-1&#x3b2; in supernatants were examined by corresponding ELISA kits (ab185986, ab178013, ab214025, Abcam). The absorbance values at 450&#xa0;nm were detected using a microplate reader (BioTek Instruments).</p>
</sec>
<sec id="s2-10">
<title>Luciferase Reporter Assay</title>
<p>Binding sequences between miR-499a-5p and NRIP1 3&#x2032; untranslated region (UTR) were predicted from starBase. The HK-2 cells were plated into 24 well plates and reached 80% confluency. Next, wide-type (Wt) and mutant-type (Mut) NRIP1 3&#x2032; UTR were inserted into pmirGLO vectors (Invitrogen) to generate pmirGLO-NRIP1-Wt and pmirGLO-NRIP1-Mut plasmids. Afterward, these vectors were cotransfected with miR-499a-5p inhibitor or NC inhibitor into HK-2 cells. After 48&#xa0;h, the luciferase activities were measured using a Lucifer Reporter Assay System (Promega, Madison, WI, United&#x20;States) and were normalized to Renilla luciferase activity.</p>
</sec>
<sec id="s2-11">
<title>RNA Pull Down Assay</title>
<p>Biotin-labeled miR-499a-5p-Wt and miR-499a-5p-Mut were synthesized by RiboBio. The cells were treated with 50&#xa0;nM of biotin-labeled NC, miR-499a-5p-Wt and miR-499a-5p-Mut for 48&#xa0;h. Next, cells were rinsed by PBS, and cultured with RIPA lysis buffer for 10&#xa0;min. Subsequently, cells were cultured at 4&#xb0;C for 3&#xa0;h. The beads were washed with precooled lysis buffer twice, low salt buffer 3&#x20;times and high salt buffer once. TRIzol was used to purify the binding RNA. Finally, RT-qPCR revealed the relative enrichment of NRIP1.</p>
</sec>
<sec id="s2-12">
<title>Statistical Analysis</title>
<p>The data obtained from &#x2265;3 independent experiments are shown as mean&#x20;&#xb1; the standard deviation. Statistical significance of difference was analyzed using Student&#x27;s t-test (for comparisons between 2 groups) and analysis of variance followed by Tukey&#x2019;s <italic>post hoc</italic> test (for comparisons more than 2 groups). <italic>p</italic>-values less than 0.05 were statistically significant. Statistical analyses were conducted using SPSS 22.0 (IBM, Armonk, NY, United&#x20;States).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Hyperoside Protects HK-2 Cells Against HG-Induced Apoptosis and Inflammation</title>
<p>First, viability of HK-2 cells under control condition, HG condition, and HG combined hyperoside condition was measured. As revealed in <xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>, cell viability was reduced by HG treatment. The inhibitory effects of HG on cell viability were rescued by hyperoside in a dose dependent way. We used 50&#xa0;nm of hyperoside in the following assays. Data from TUNEL assays <bold>(</bold>
<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>) and flow cytometry analysis (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>
<bold>)</bold> indicated that cell apoptosis was induced by HG treatment and was reduced by hyperoside. Western blot analysis revealed that increased Bax expression and decreased Bcl-2 expression induced by HG were rescued by hyperoside (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>). Furthermore, protein levels of IL-10, IL-6 and IL-1&#x3b2; in HG-treated HK-2 cells were measured. HG-induced upregulation of IL-6 and IL-1&#x3b2; protein levels and downregulation of IL-10 protein levels, and hyperoside rescued the influence of HG treatment on IL-10, IL-6 and IL-1&#x3b2; (<xref ref-type="fig" rid="F1">Figure&#x20;1E</xref>). Finally, concentrations of these proinflammatory cytokines were detected by ELISA kits. The results indicated that hyperoside reversed the stimulating influence of HG on inflammatory response of HK-2 cells (<xref ref-type="fig" rid="F1">Figure&#x20;1F</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Hyperoside protects HK-2 cells against HG-induced apoptosis and inflammation. <bold>(A)</bold> Viability of HK-2 cells by different treatments was measured by CCK-8 assay. <bold>(B, C)</bold> TUNEL and FITC/PI staining assays revealed apoptosis of HK-2 cells by different treatments: control; HG; HG &#x2b; hyperoside. <bold>(D)</bold> Bcl-2 and Bax proteins were detected using western blotting performed on extracts of HK-2 cells. <bold>(E)</bold> Influence of hyperoside on IL-10, IL-6 and IL-1&#x3b2; proteins in HG induced HK-2 cells. <bold>(F)</bold> ELISA revealed IL-10, IL-6 and IL-1&#x3b2; contents in HK-2 cells by different treatments: control; HG; HG &#x2b; hyperoside. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, ns indicates no significance.</p>
</caption>
<graphic xlink:href="pore-27-629829-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Hyperoside alleviates HG-induced apoptosis and inflammation by upregulation of miR-499a-5p</title>
<p>Next, we identified that miR-499a-5p was downregulated by HG and was further dose-dependently upregulated by hyperoside in HK-2 cells (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). RT-qPCR was applied to detect the knockdown efficacy of miR-499a-5p in HG treated HK-2 cells. Data in <xref ref-type="fig" rid="F2">Figure&#x20;2B</xref> suggested that miR-499a-5p expression was effectively knocked down by miR-499a-5p inhibitor. MiR-499a-5p inhibitor rescued the antiapoptotic effects of hyperoside on HG-treated HK-2 cells (<xref ref-type="fig" rid="F2">Figures 2C&#x2013;E</xref>). Results from Western blot analysis (<xref ref-type="fig" rid="F2">Figure&#x20;2F</xref>) and ELISA (<xref ref-type="fig" rid="F2">Figure&#x20;2G</xref>) showed that miR-499a-5p inhibition rescued the increase of IL-10 levels, and the decrease of IL-6 and IL-1&#x3b2; levels induced by hyperoside in HG treated HK-2&#x20;cells.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Hyperoside alleviates HG-induced apoptosis and inflammation by upregulation of miR-499a-5p. <bold>(A)</bold> RT-qPCR was performed on extracts of HK-2 cells under different treatments: control; HG; HG &#x2b; hyperoside to detect miR-499a-5p expression. <bold>(B)</bold> Knockdown efficiency of miR-499a-5p in HG-treated HK-2 cells was evaluated by RT-qPCR. <bold>(C,D)</bold> TUNEL and FITC/PI staining assays were applied to detect influence of miR-499a-5p inhibitor on hyperoside in HG-treated HK-2 cells. <bold>(E)</bold> Western blotting revealed Bcl-2 and Bax proteins. <bold>(F,G)</bold> Western blotting and ELISA were performed to reveal IL-10, IL-6 and IL-1&#x3b2; levels. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, ns indicates no significance.</p>
</caption>
<graphic xlink:href="pore-27-629829-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>MiR-499a-5p Targets NRIP1 in HK-2 Cells</title>
<p>NRIP1 was identified as a downstream target of miR-499a-5p based on starbase prediction. HG resulted in upregulation of NRIP1, and hyperoside treatment dose-dependently reduced its expression in HK-2 cells <bold>(</bold>
<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). MiR-499a-5p inhibitor promoted NRIP1 mRNA and protein levels in HK-2 cells regardless of HG treatment (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>). The binding sequences of miR-499a-5p and NRIP1 were predicted from starBase and were shown in <xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>. Binding site of NRIP1 was mutated for the next luciferase reporter assay. As indicated in <xref ref-type="fig" rid="F3">Figure&#x20;3E</xref>, transfection of miR-499a-5p inhibitor enhanced the luciferase activity of pmirGLO-NRIP1-Wt plasmids and had no significance influence on that of pmirGLO-NRIP1-Mut plasmids in HK-2 cells regardless of HG treatment. Moreover, data of RNA pulldown assay showed that NRIP1 was abundantly enriched in products pulled down by bio-miR-499a-5p Wt, compared with that pulled down by bio-miR-499a-5p Mut, indicating the interaction of miR-499a-5p and NRIP1&#x20;<bold>(</bold>
<xref ref-type="fig" rid="F3">Figure&#x20;3F</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>MiR-499a-5p targets NRIP1 in HK-2 cells. <bold>(A)</bold> RT-qPCR was performed on extracts of HK-2 cells under different treatments: control; HG; HG &#x2b; hyperoside to detect expression of NRIP1. <bold>(B, C)</bold> The influence of miR-499a-5p inhibitor on NRIP1 mRNA and protein expression in HK-2 cells with or without HG treatment. <bold>(D)</bold> Binding site of miR-499a-5p and NRIP1 was predicted from starBase. <bold>(E)</bold> Luciferase activity of pmirGLO-NRIP1-Wt and pmirGLO-NRIP1-Mut plasmids in HK-2 cells transfected with miR-499a-5p inhibitor. <bold>(F)</bold> A RNA pull down assay was applied to detect relative enrichment of NRIP1. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, ns indicates no significance.</p>
</caption>
<graphic xlink:href="pore-27-629829-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Hyperoside Suppresses Apoptosis and Inflammatory Response in HG-Treated HK-2 Cells via the miR-499a-5p/NRIP1 Pathway</title>
<p>Finally, the rescue assays were conducted. <xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref> revealed that NRIP1 inhibition rescued the proapoptotic influences of miR-499a-5p on HK-2 cells. The stimulating effects of silenced miR-499a-5p on protein levels of IL-10, IL-6 and IL-1&#x3b2; were rescued by downregulation of NRIP1 (<xref ref-type="fig" rid="F4">Figures 4D,E</xref>). Hyperoside induced apoptosis of 786&#x2013;0 cells, while neither miR-499a-5p nor NRIP1 had rescue effects on hyperoside induced apoptosis of 786&#x2013;0 cells (<xref ref-type="sec" rid="s9">Supplementary Figures S1A,B</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Hyperoside suppresses apoptosis and inflammation of HG-treated HK-2 cells via the miR-499a-5p/NRIP1 pathway. <bold>(A, B)</bold> TUNEL and FITC/PI staining assays revealed apoptosis of HG-treated HK-2 cells by different treatments: hyperoside; hyperoside &#x2b; miR-499a-5p inhibitor; hyperoside &#x2b; miR-499a-5p inhibitor &#x2b; sh-NRIP1. <bold>(C)</bold> Western blotting performed on extracts of HK-2 cells was conducted to reveal Bcl-2 and Bax proteins. <bold>(D, E)</bold> Western blotting and ELISA were performed to reveal IL-10, IL-6 and IL-1&#x3b2; levels. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="pore-27-629829-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Our findings revealed that HG treatment induced apoptosis and inflammatory response of HK-2 cells, and hyperoside protected HK-2 cells against HG induced apoptosis and inflammation. MiR-499a-5p is downregulated by HG treatment in HK-2 cells. Hyperoside can induce the upregulation of miR-499a-5p. Hyperoside inhibited apoptosis and inflammation of HG treated HK-2 cells by upregulation of miR-499a-5p. Furthermore, miR-499a-5p targeted NRIP1 3&#x2032;UTR to inhibit its mRNA expression, and further reduce its translation.</p>
<p>MiRNAs play significant roles in apoptosis and inflammatory response of HK-2 cells, for example, Arbutin upregulates miR-27a to inhibit apoptosis of HK-2 cells stimulated by HG [<xref ref-type="bibr" rid="B24">24</xref>]. MiR-34b targets IL-6R to alleviate HG-stimulated inflammatory response and apoptosis of HK-2 Cells [<xref ref-type="bibr" rid="B25">25</xref>]. MiR-455-3p decreased ROCK2 to reduce inflammatory cytokine levels in HG stimulated HK-2 cells [<xref ref-type="bibr" rid="B26">26</xref>]. In the present study, HG treatment induced the low expression of miR-499a-5p in HK-2 cells, and hyperoside rescued the downregulation of miR-499a-5p caused by HG in HK-2 cells. Inhibition of miR-499a-5p rescued the protective effects of hyperoside on apoptosis and inflammation of HG treated HK-2 cells. MiR-499a-5p expression has been found to be decreased in the livers of mice fed a high-fat diet, and is associated with the insulin signaling pathway and glycogen synthesis [<xref ref-type="bibr" rid="B27">27</xref>]. Levels of miR-499-5p are reduced in erythrocytes of African American pre-diabetic patients [<xref ref-type="bibr" rid="B28">28</xref>]. A similar expression pattern of miR-499-5p is also found in patients&#x20;with DN or diabetic polyneuropathy [<xref ref-type="bibr" rid="B29">29</xref>]. In addition, miR-499-5p is downregulated among patients with diabetic end-stage renal disease&#x20;[<xref ref-type="bibr" rid="B30">30</xref>].</p>
<p>Subsequently, NRIP1 was verified as the downstream target of miR-499a-5p. NRIP1 inhibition rescued the effects of miR-499a-5p inhibitor on hyperoside in HG-stimulated HK-2 cells, indicating the putative role of NRIP1 in DN. NRIP1 is also named as receptor-interacting protein 140 (RIP140). The RIP140 protein functions as a coactivator or a corepressor following its recruitment to target genes [<xref ref-type="bibr" rid="B31">31</xref>], and is essential in glucose metabolism [<xref ref-type="bibr" rid="B32">32</xref>]. Xue et&#x20;al. have revealed that NRIP1 is associated with subclinical inflammation in patients with type 2 diabetes [<xref ref-type="bibr" rid="B33">33</xref>]. RIP140 was shown to induce the expression of proinflammatory factors including IL-6, and IL-1&#x3b2; [<xref ref-type="bibr" rid="B34">34</xref>]. RIP140 degradation facilitates the alteration of activity of several proinflammatory cytokines in endotoxin tolerance [<xref ref-type="bibr" rid="B35">35</xref>]. RIP140 has the proinflammatory potential in response to alteration of the intracellular cholesterol status in macrophages [<xref ref-type="bibr" rid="B36">36</xref>]. Moreover, RIP140 was found to exert regulatory functions in acute and chronic inflammatory diseases [<xref ref-type="bibr" rid="B37">37</xref>]. Hyperoside has been reported to induce apoptosis of 786-O renal cancer cells by miR-27a [<xref ref-type="bibr" rid="B38">38</xref>], indicating the important role of botanicals and their derivates in the anticancer activity. The present study revealed that 786-O cell apoptosis was promoted by hyperoside. Neither miR-499a-5p nor NRIP1 had rescue effects on hyperoside induced apoptosis of 786-0&#x20;cells.</p>
<p>In conclusion, our findings innovatively revealed that hyperoside protected HK-2 cells against HG-stimulated apoptosis and inflammation via the miR-499a-5p/NRIP1 axis (<xref ref-type="sec" rid="s9">Supplementary Figure S2</xref>). However, this study only focused on <italic>in&#x20;vitro</italic> model, which is a limitation of the present study. Our future research will focus on the <italic>in vivo</italic> model systems. Furthermore, HK-2 is a human papillomavirus 16 transformed cell line and is used as a model as normal tubular cell with limitations, which reacts differently to primary epithelial&#x20;cells.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The datasets used during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>JZ conceived and designed the experiments. SZ, XS, YL, and JY carried out the experiments. JZ and JY analyzed the data. JZ and JY drafted the manuscript. All authors agreed to be accountable for all aspects of the work. All authors have read and approved the final manuscript.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by Jiangsu Provincial Hospital of Traditional Chinese Medicine (No. Y2019CX36).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="supplementary_material" id="s9">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.por-journal.com/articles/10.3389/pore.2021.629829/full#supplementary-material">https://www.por-journal.com/articles/10.3389/pore.2021.629829/full&#x23;supplementary-material</ext-link>.</p>
<supplementary-material xlink:href="Image1.TIF" id="SM1" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.TIF" id="SM2" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ME.</given-names>
</name>
</person-group> <article-title>Diabetic nephropathy</article-title>. <source>Diabetes Technol Ther</source> (<year>1999</year>). <volume>1</volume>(<issue>4</issue>):<fpage>489</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1089/152091599317044</pub-id> </citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Prevalence and control of diabetes in Chinese adults</article-title>. <source>Jama</source> (<year>2013</year>). <volume>310</volume>(<issue>9</issue>):<fpage>948</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.168118</pub-id> </citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shaha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zanchi</surname>
<given-names>A</given-names>
</name>
</person-group> <article-title>Multidisciplinary management of diabetic kidney disease</article-title>. <source>JBI Database Syst Rev Implementation Rep</source> (<year>2016</year>). <volume>14</volume>(<issue>7</issue>):<fpage>169</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.11124/jbisrir-2016-003011</pub-id> </citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mesarosova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ochodnicky</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Leemans</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Florquin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krenek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klimas</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>High glucose induces HGF-independent activation of met receptor in human renal tubular epithelium</article-title>. <source>J&#x20;Receptors Signal Transduction</source> (<year>2017</year>). <volume>37</volume>(<issue>6</issue>):<fpage>535</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1080/10799893.2017.1365902</pub-id> </citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habib</surname>
<given-names>SL.</given-names>
</name>
</person-group> <article-title>Diabetes and renal tubular cell apoptosis</article-title>. <source>World J&#x20;Diabetes</source> (<year>2013</year>). <volume>4</volume>(<issue>2</issue>):<fpage>27</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.4239/wjd.v4.i2.27</pub-id> </citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kashihara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Makino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>Z.</given-names>
</name>
</person-group> <article-title>Apoptosis in glomerular sclerosis</article-title>. <source>Kidney Int</source> (<year>1996</year>). <volume>49</volume>(<issue>1</issue>):<fpage>103</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/ki.1996.14</pub-id> </citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truong</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Petrusevska</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gurpinar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shappell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lechago</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Cell apoptosis and proliferation in experimental chronic obstructive uropathy</article-title>. <source>Kidney Int</source> (<year>1996</year>). <volume>50</volume>(<issue>1</issue>):<fpage>200</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/ki.1996.303</pub-id> </citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Savill</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nahas</surname>
<given-names>AME.</given-names>
</name>
</person-group> <article-title>Cellular apoptosis and proliferation in experimental renal fibrosis</article-title>. <source>Nephrol Dial Transpl</source> (<year>1998</year>). <volume>13</volume>(<issue>9</issue>):<fpage>2216</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/13.9.2216</pub-id> </citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Konishi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kodama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tsujimoto</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death</article-title>. <source>Proc Natl Acad Sci</source> (<year>2000</year>). <volume>97</volume>(<issue>7</issue>):<fpage>3100</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.97.7.3100</pub-id> </citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garc&#xed;a</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Navarro-Gonz&#xe1;lez</surname>
<given-names>JF.</given-names>
</name>
</person-group> <article-title>Pathogenic perspectives for the role of inflammation in diabetic nephropathy</article-title>. <source>Clin Sci</source> (<year>2009</year>). <volume>116</volume>(<issue>6</issue>):<fpage>479</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1042/cs20080394</pub-id> </citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro-Gonz&#xe1;lez</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Mora-Fern&#xe1;ndez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Fuentes</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Garc&#xed;a-P&#xe9;rez</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</article-title>. <source>Nat Rev Nephrol</source> (<year>2011</year>). <volume>7</volume>(<issue>6</issue>):<fpage>327</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2011.51</pub-id> </citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>D.</given-names>
</name>
</person-group> <article-title>Antioxidant activity of a flavonoid-rich extract of hypericum perforatumL.<italic>in Vitro</italic>
</article-title>. <source>J&#x20;Agric Food Chem</source> (<year>2004</year>). <volume>52</volume>(<issue>16</issue>):<fpage>5032</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/jf049571r</pub-id> </citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S-J</given-names>
</name>
<name>
<surname>Um</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J-Y.</given-names>
</name>
</person-group> <article-title>Anti-inflammatory activity of hyperoside through the suppression of nuclear factor-&#x3ba;b activation in mouse peritoneal macrophages</article-title>. <source>Am J&#x20;Chin Med</source> (<year>2011</year>). <volume>39</volume>(<issue>1</issue>):<fpage>171</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1142/s0192415x11008737</pub-id> </citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ku</surname>
<given-names>S-K</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>O-J</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J-S.</given-names>
</name>
</person-group> <article-title>Hyperoside inhibits high-glucose-induced vascular inflammation <italic>in&#x20;vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Inflammation</source> (<year>2014</year>). <volume>37</volume>(<issue>5</issue>):<fpage>1389</fpage>&#x2013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-014-9863-8</pub-id> </citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ku</surname>
<given-names>S-K</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M-S</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J-S.</given-names>
</name>
</person-group> <article-title>Anti-inflammatory effects of hyperoside in human endothelial cells and in mice</article-title>. <source>Inflammation</source> (<year>2015</year>). <volume>38</volume>(<issue>2</issue>):<fpage>784</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-014-9989-8</pub-id> </citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
</person-group> <article-title>Protective effect of hyperoside on heart failure rats via attenuating myocardial apoptosis and inducing autophagy</article-title>. <source>Biosci Biotechnol Biochem</source> (<year>2020</year>). <volume>84</volume>(<issue>4</issue>):<fpage>714</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1080/09168451.2019.1685369</pub-id> </citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>An</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Protective effect of hyperoside against renal ischemia-reperfusion injury via modulating mitochondrial fission, oxidative stress, and apoptosis</article-title>. <source>Free Radic Res</source> (<year>2019</year>). <volume>53</volume>(<issue>7</issue>):<fpage>727</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1080/10715762.2019.1623883</pub-id> </citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Q-L.</given-names>
</name>
</person-group> <article-title>LncRNA MIR503HG promotes high-glucose-induced proximal tubular cell apoptosis by targeting miR-503-5p/bcl-2 pathway</article-title>. <source>Dmso</source> (<year>2020</year>). <volume>Vol. 13</volume>:<fpage>4507</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.2147/dmso.s277869</pub-id> </citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
</person-group> <article-title>Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy</article-title>. <source>Free Radic Biol Med</source> (<year>2020</year>). <volume>162</volume>:<fpage>435</fpage>&#x2013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.10.323</pub-id> </citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Khazim</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Campisi-Pinto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bar-Sela</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>I.</given-names>
</name>
</person-group> <article-title>Glucose induces IL-1&#x3b1;-dependent inflammation and extracellular matrix proteins expression and deposition in renal tubular epithelial cells in diabetic kidney disease</article-title>. <source>Front Immunol</source> (<year>2020</year>). <volume>11</volume>:<fpage>1270</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01270</pub-id> </citation>
</ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>L-H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J-H.</given-names>
</name>
</person-group> <article-title>starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data</article-title>. <source>Nucl Acids Res</source> (<year>2014</year>). <volume>42</volume>(<issue>D1</issue>):<fpage>D92</fpage>&#x2013;<lpage>D97</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1248</pub-id> </citation>
</ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>TD.</given-names>
</name>
</person-group> <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2&#x2212;&#x394;&#x394;CT method</article-title>. <source>Methods</source> (<year>2001</year>). <volume>25</volume>(<issue>4</issue>):<fpage>402</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id> </citation>
</ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>LL</given-names>
</name>
<etal/>
</person-group> <article-title>EGCG attenuates renal damage via reversing klotho hypermethylation in diabetic db/db mice and HK-2 cells</article-title>. <source>Oxid Med Cel Longev</source> (<year>2020</year>). <volume>2020</volume>:<fpage>6092715</fpage>. <pub-id pub-id-type="doi">10.1155/2020/6092715</pub-id> </citation>
</ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
</person-group> <article-title>Arbutin protects HK-2 cells against high glucose-induced apoptosis and autophagy by up-regulating microRNA-27a</article-title>. <source>Artif Cell Nanomedicine Biotechnol</source> (<year>2019</year>). <volume>47</volume>(<issue>1</issue>):<fpage>2940</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2019.1640231</pub-id> </citation>
</ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group> <article-title>miR-34b alleviates high glucose-induced inflammation and apoptosis in human HK-2 cells via IL-6R/JAK2/STAT3 signaling pathway</article-title>. <source>Med Sci Monit</source> (<year>2019</year>). <volume>25</volume>:<fpage>8142</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.12659/msm.917128</pub-id> </citation>
</ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>MiR-455-3p suppresses renal fibrosis through repression of ROCK2 expression in diabetic nephropathy</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2018</year>). <volume>503</volume>(<issue>2</issue>):<fpage>977</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.06.105</pub-id> </citation>
</ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>H-p.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z-y.</given-names>
</name>
</person-group> <article-title>MiR-499-5p contributes to hepatic insulin resistance by suppressing PTEN</article-title>. <source>Cell Physiol Biochem</source> (<year>2015</year>). <volume>36</volume>(<issue>6</issue>):<fpage>2357</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1159/000430198</pub-id> </citation>
</ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fluitt</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nunlee-Bland</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nekhai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gambhir</surname>
<given-names>KK.</given-names>
</name>
</person-group> <article-title>miRNA-15a, miRNA-15b, and miRNA-499 are reduced in erythrocytes of pre-diabetic african-American adults</article-title>. <source>Jacobs J&#x20;Diabetes Endocrinol</source> (<year>2016</year>). <volume>2</volume>(<issue>1</issue>):<fpage>014</fpage> </citation>
</ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciccacci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Latini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Politi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>D&#x27;Amato</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lauro</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes</article-title>. <source>J&#x20;Diabetes its Complications</source> (<year>2018</year>). <volume>32</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdiacomp.2017.10.011</pub-id> </citation>
</ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fawzy</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Abu AlSel</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Al Ageeli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Al-Qahtani</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Abdel-Daim</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Toraih</surname>
<given-names>EA.</given-names>
</name>
</person-group> <article-title>Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis</article-title>. <source>Arch Physiol Biochem</source> (<year>2020</year>). <volume>126</volume>(<issue>2</issue>):<fpage>172</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1080/13813455.2018.1499119</pub-id> </citation>
</ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#x27;Horset</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dauvois</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heery</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Cavaill&#xe8;s</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>MG.</given-names>
</name>
</person-group> <article-title>RIP-140 interacts with multiple nuclear receptors by means of two distinct sites</article-title>. <source>Mol Cel Biol.</source> (<year>1996</year>). <volume>16</volume>(<issue>11</issue>):<fpage>6029</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.16.11.6029</pub-id> </citation>
</ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steel</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pocock</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kumaran</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Fritah</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle</article-title>. <source>Cel Metab</source> (<year>2007</year>). <volume>6</volume>(<issue>3</issue>):<fpage>236</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2007.08.004</pub-id> </citation>
</ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>RIP140 is associated with subclinical inflammation in type 2 diabetic patients</article-title>. <source>Exp Clin Endocrinol Diabetes</source> (<year>2013</year>). <volume>121</volume>(<issue>1</issue>):<fpage>37</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1055/s-0032-1323683</pub-id> </citation>
</ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zschiedrich</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hardeland</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Krones-Herzig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Berriel Diaz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vegiopoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>M&#xfc;ggenburg</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Coactivator function of RIP140 for NF&#x3ba;B/RelA-dependent cytokine gene expression</article-title>. <source>Blood</source> (<year>2008</year>). <volume>112</volume>(<issue>2</issue>):<fpage>264</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2007-11-121699</pub-id> </citation>
</ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>P-C</given-names>
</name>
<name>
<surname>Tsui</surname>
<given-names>Y-C</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Greaves</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>L-N</given-names>
</name>
</person-group> <article-title>NF-&#x3ba;B-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance</article-title>. <source>Nat Immunol</source> (<year>2012</year>). <volume>13</volume>(<issue>4</issue>):<fpage>379</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2238</pub-id> </citation>
</ref>
<ref id="B36">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>P-C</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>K-C</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>Y-S</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>L-N.</given-names>
</name>
</person-group> <article-title>Cholesterol regulation of receptor&#x2010;interacting protein 140 via microRNA&#x2010;33 in inflammatory cytokine production</article-title>. <source>FASEB j.</source> (<year>2011</year>). <volume>25</volume>(<issue>5</issue>):<fpage>1758</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-179267</pub-id> </citation>
</ref>
<ref id="B37">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>Z-J</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
</person-group> <article-title>Transcriptional co-regulator RIP140: an important mediator of the inflammatory response and its associated diseases</article-title>. <source>Mol Med Rep</source> (<year>2017</year>). <volume>16</volume>(<issue>2</issue>):<fpage>994</fpage>&#x2013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.6683</pub-id> </citation>
</ref>
<ref id="B38">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y-F</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G-C</given-names>
</name>
<etal/>
</person-group> <article-title>Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a</article-title>. <source>Oncol Rep</source> (<year>2014</year>). <volume>31</volume>(<issue>1</issue>):<fpage>117</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.3892/or.2013.2811</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>